The estimated Net Worth of Shawn Tomasello is at least $2.28 Million dollars as of 30 September 2022. Ms. Tomasello owns over 9,677 units of UroGen Pharma Ltd stock worth over $161,259 and over the last 9 years she sold URGN stock worth over $1,810,597. In addition, she makes $312,698 as Independent Director at UroGen Pharma Ltd.
Shawn has made over 7 trades of the UroGen Pharma Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 9,677 units of URGN stock worth $14,999 on 30 September 2022.
The largest trade she's ever made was buying 9,677 units of UroGen Pharma Ltd stock on 30 September 2022 worth over $14,999. On average, Shawn trades about 670 units every 53 days since 2015. As of 30 September 2022 she still owns at least 11,677 units of UroGen Pharma Ltd stock.
You can see the complete history of Ms. Tomasello stock trades at the bottom of the page.
Shawn Cline Tomasello is Independent Director of the Company. Ms. Tomasello most recently served as Chief Commercial Officer of Kite Pharma, Inc. (subsequently Kite, a Gilead Company). Prior to joining Kite, Ms. Tomasello served as Chief Commercial Officer at Pharmacyclics, Inc. Previously, she held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for five brands encompassing 11 indications. Prior to this, she was National Director of Hematology for Rituxan at Genentech. Earlier in her career, Ms. Tomasello held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble. She currently serves on the Boards of Centrexion Therapeutics, Oxford BioTherapeutics, Mesoblast, Gamida Cell, and Diplomat Specialty. Ms. Tomasello holds a B.S. degree in marketing from the University of Cincinnati and an M.B.A. from Murray State University, Kentucky. Our Board believes Ms. Tomasello’s leadership and management experience qualifies her to serve on our board of directors.
As the Independent Director of UroGen Pharma Ltd, the total compensation of Shawn Tomasello at UroGen Pharma Ltd is $312,698. There are 12 executives at UroGen Pharma Ltd getting paid more, with Elizabeth Barrett having the highest compensation of $25,900,800.
Shawn Tomasello is 61, she's been the Independent Director of UroGen Pharma Ltd since 2018. There are 5 older and 10 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.
Shawn's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at UroGen Pharma Ltd have traded over $8,740,363 worth of UroGen Pharma Ltd stock and bought 33,940 units worth $791,524 . The most active insiders traders include Ran Nussbaum, Arie Belldegrun und Kathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of $214,027. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth $138,100.
urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.
UroGen Pharma Ltd executives and other stock owners filed with the SEC include: